Furosemide as a fetal growth promoter

E. Czeizel, M. Rockenbauer, Attila Mosonyi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To study the effect of furosemide treatment on fetal growth during pregnancy. Design and Setting: The control dataset of the Hungarian Case-Control Surveillance of Congenital Anomalies between 1980 and 1996 was used. Information on furosemide drug exposure was obtained retrospectively from pregnant mothers by means of a questionnaire, and prospectively on the basis of antenatal care log books. Study Participants: 38,151 pregnant women who had babies without any congenital abnormalities. Main Outcome Measures: Medically recorded birthweights and gestational ages of 450 newborn infants born to mothers receiving furosemide treatment during pregnancy, and of 37,621 newborn infants born to mothers without furosemide treatment. Results: During the study period, 1.2% of the included pregnant women were treated with furosemide, mainly in the third trimester of gestation. The mean birthweight was significantly higher (by 123 g) and the proportion of low birthweight infants was significantly lower (by 1.7 times) with furosemide treatment during pregnancy (p = 0.01). The mean gestational age was not modified by furosemide treatment but the proportion with preterm births was higher due to the underlying maternal disorders and complications of the pregnancy. Conclusion: Furosemide is a fetal growth promoter. This is probably a result of indirect effects through the mother; however, clarification of the mechanism requires further study.

Original languageEnglish
Pages (from-to)53-60
Number of pages8
JournalClinical Drug Investigation
Volume20
Issue number1
Publication statusPublished - 2000

Fingerprint

Furosemide
Fetal Development
Mothers
Pregnancy
Gestational Age
Pregnant Women
Newborn Infant
Therapeutics
Prenatal Care
Pregnancy Complications
Premature Birth
Third Pregnancy Trimester
Outcome Assessment (Health Care)
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Furosemide as a fetal growth promoter. / Czeizel, E.; Rockenbauer, M.; Mosonyi, Attila.

In: Clinical Drug Investigation, Vol. 20, No. 1, 2000, p. 53-60.

Research output: Contribution to journalArticle

Czeizel, E. ; Rockenbauer, M. ; Mosonyi, Attila. / Furosemide as a fetal growth promoter. In: Clinical Drug Investigation. 2000 ; Vol. 20, No. 1. pp. 53-60.
@article{081c638ae1984d80ac0ec8e4469893a9,
title = "Furosemide as a fetal growth promoter",
abstract = "Objective: To study the effect of furosemide treatment on fetal growth during pregnancy. Design and Setting: The control dataset of the Hungarian Case-Control Surveillance of Congenital Anomalies between 1980 and 1996 was used. Information on furosemide drug exposure was obtained retrospectively from pregnant mothers by means of a questionnaire, and prospectively on the basis of antenatal care log books. Study Participants: 38,151 pregnant women who had babies without any congenital abnormalities. Main Outcome Measures: Medically recorded birthweights and gestational ages of 450 newborn infants born to mothers receiving furosemide treatment during pregnancy, and of 37,621 newborn infants born to mothers without furosemide treatment. Results: During the study period, 1.2{\%} of the included pregnant women were treated with furosemide, mainly in the third trimester of gestation. The mean birthweight was significantly higher (by 123 g) and the proportion of low birthweight infants was significantly lower (by 1.7 times) with furosemide treatment during pregnancy (p = 0.01). The mean gestational age was not modified by furosemide treatment but the proportion with preterm births was higher due to the underlying maternal disorders and complications of the pregnancy. Conclusion: Furosemide is a fetal growth promoter. This is probably a result of indirect effects through the mother; however, clarification of the mechanism requires further study.",
author = "E. Czeizel and M. Rockenbauer and Attila Mosonyi",
year = "2000",
language = "English",
volume = "20",
pages = "53--60",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Furosemide as a fetal growth promoter

AU - Czeizel, E.

AU - Rockenbauer, M.

AU - Mosonyi, Attila

PY - 2000

Y1 - 2000

N2 - Objective: To study the effect of furosemide treatment on fetal growth during pregnancy. Design and Setting: The control dataset of the Hungarian Case-Control Surveillance of Congenital Anomalies between 1980 and 1996 was used. Information on furosemide drug exposure was obtained retrospectively from pregnant mothers by means of a questionnaire, and prospectively on the basis of antenatal care log books. Study Participants: 38,151 pregnant women who had babies without any congenital abnormalities. Main Outcome Measures: Medically recorded birthweights and gestational ages of 450 newborn infants born to mothers receiving furosemide treatment during pregnancy, and of 37,621 newborn infants born to mothers without furosemide treatment. Results: During the study period, 1.2% of the included pregnant women were treated with furosemide, mainly in the third trimester of gestation. The mean birthweight was significantly higher (by 123 g) and the proportion of low birthweight infants was significantly lower (by 1.7 times) with furosemide treatment during pregnancy (p = 0.01). The mean gestational age was not modified by furosemide treatment but the proportion with preterm births was higher due to the underlying maternal disorders and complications of the pregnancy. Conclusion: Furosemide is a fetal growth promoter. This is probably a result of indirect effects through the mother; however, clarification of the mechanism requires further study.

AB - Objective: To study the effect of furosemide treatment on fetal growth during pregnancy. Design and Setting: The control dataset of the Hungarian Case-Control Surveillance of Congenital Anomalies between 1980 and 1996 was used. Information on furosemide drug exposure was obtained retrospectively from pregnant mothers by means of a questionnaire, and prospectively on the basis of antenatal care log books. Study Participants: 38,151 pregnant women who had babies without any congenital abnormalities. Main Outcome Measures: Medically recorded birthweights and gestational ages of 450 newborn infants born to mothers receiving furosemide treatment during pregnancy, and of 37,621 newborn infants born to mothers without furosemide treatment. Results: During the study period, 1.2% of the included pregnant women were treated with furosemide, mainly in the third trimester of gestation. The mean birthweight was significantly higher (by 123 g) and the proportion of low birthweight infants was significantly lower (by 1.7 times) with furosemide treatment during pregnancy (p = 0.01). The mean gestational age was not modified by furosemide treatment but the proportion with preterm births was higher due to the underlying maternal disorders and complications of the pregnancy. Conclusion: Furosemide is a fetal growth promoter. This is probably a result of indirect effects through the mother; however, clarification of the mechanism requires further study.

UR - http://www.scopus.com/inward/record.url?scp=0033926066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033926066&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033926066

VL - 20

SP - 53

EP - 60

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 1

ER -